Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Mortality from 9 March 2006 to 1 January 2015 in patients with rheumatoid arthritis who received alemtuzumab between 1991 and 1994

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Age at death, years Cause of death
78 Carcinomatosis, unknown primary, rheumatoid arthritis
79 Bronchopneumonia, rheumatoid arthritis, cellulitis
58 Respiratory failure, pulmonary oedema
89 Bronchopneumonia, congestive cardiac failure
77 Pneumonia, vascular dementia
71 Brain tumour
76 Sepsis, urinary tract infection, chronic obstructive pulmonary disease, rheumatoid arthritis
69 Adenocarcinoma of the lung
79 Pulmonary fibrosis
75 Dementia, rheumatoid arthritis